Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
The company announced positive topline data from the Phase 3 ADorable-1 trial
The company announced positive topline data from the Phase 3 ADorable-1 trial
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The trial will enroll up to 42 patients in Finland across four cohorts
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Subscribe To Our Newsletter & Stay Updated